News

IOL Chemicals and Pharmaceuticals approved INR 4.95 billion (about RMB 347 million) to add 6,000 tonnes/year of ibuprofen API capacity at its Barnala site in Punjab, lifting total capacity from 12,000 to 18,000 tonnes/year, a 50% increase. Commercial production is expected in December 2027. Existing capacity runs near 95% utilization, and IOL holds roughly 30% of the global ibuprofen API market, with integrated upstream intermediates such as isobutylbenzene. The investment also covers a formulat

CNS drug development is shifting as brain-shuttle delivery, gene therapy, multi-target strategies and AI-assisted discovery move from concept toward practice. The blood-brain barrier has long limited brain exposure, and diseases like Alzheimer's involve interconnected mechanisms. In 2026, the Alzheimer's pipeline lists 158 drugs across 192 trials, with disease-targeted therapies dominating and research spanning amyloid, tau, inflammation and synaptic function. Brain-shuttle technology uses recep

India's Drugs Technical Advisory Board has recommended amendments to the New Drugs and Clinical Trials Rules, 2019, to clarify GMP requirements for new drugs and APIs made for clinical trials, BA/BE studies, and non-clinical testing. At its 94th meeting on August 27, 2026, the DTAB proposed changes to Rules 55 and 63, separating clinical-development manufacturing from analytical or non-clinical material. Clinical trial and BA/BE batches would require GMP-compliant facilities under the Drugs Rule